Inhibition of myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc

Takuya Fukazawa, Yutaka Maeda, Junji Matsuoka, Tomoki Yamatsuji, Kaoru Shigemitsu, Ichiro Morita, Francesco Faiola, Mary L. Durbin, Laura Soucek, Yoshio Naomoto

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Myc is an oncogenic transcription factor that promotes tumorigenesis. Recently, a dominant negative form of Myc (Omomyc) was shown to cause regression of lung tumors in a mouse model of lung cancer caused by KRAS mutation, suggesting that Myc might be a potential therapeutic target to treat the KRAS lung cancer. However, it is not yet known whether Omomyc can also inhibit the growth of human lung tumors that carry a similar KRAS mutation. In the present study, we demonstrate that Omomyc induces cell death of KRAS-mutated human lung adenocarcinoma A549 cells in vitro and in vivo. However, Omomyc does not induce cell death in human lung adenocarcinoma H441 cells that also carry the KRAS mutation. Interestingly, A549 cells express high levels of Myc, while H441 cells do not. Co-expression of exogenous Myc with Omomyc in H441 cells induces cell death, indicating that Omomyc requires high levels of Myc to induce cell death in KRAS mutation-positive lung adenocarcinoma. Here, we show for the first time that KRAS mutation-positive lung cancer displaying high levels of Myc could be treated by inhibiting Myc transactivation function.

Original languageEnglish
Pages (from-to)4193-4200
Number of pages8
JournalAnticancer Research
Volume30
Issue number10
Publication statusPublished - Oct 2010

Fingerprint

Lung Neoplasms
Cell Death
Mutation
Lung
Transcriptional Activation
Neoplasms
Carcinogenesis
Transcription Factors
Growth
Adenocarcinoma of lung
A549 Cells
Therapeutics

Keywords

  • A549
  • KRAS lung cancer
  • Myc
  • Omomyc

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fukazawa, T., Maeda, Y., Matsuoka, J., Yamatsuji, T., Shigemitsu, K., Morita, I., ... Naomoto, Y. (2010). Inhibition of myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Research, 30(10), 4193-4200.

Inhibition of myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. / Fukazawa, Takuya; Maeda, Yutaka; Matsuoka, Junji; Yamatsuji, Tomoki; Shigemitsu, Kaoru; Morita, Ichiro; Faiola, Francesco; Durbin, Mary L.; Soucek, Laura; Naomoto, Yoshio.

In: Anticancer Research, Vol. 30, No. 10, 10.2010, p. 4193-4200.

Research output: Contribution to journalArticle

Fukazawa, T, Maeda, Y, Matsuoka, J, Yamatsuji, T, Shigemitsu, K, Morita, I, Faiola, F, Durbin, ML, Soucek, L & Naomoto, Y 2010, 'Inhibition of myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc', Anticancer Research, vol. 30, no. 10, pp. 4193-4200.
Fukazawa T, Maeda Y, Matsuoka J, Yamatsuji T, Shigemitsu K, Morita I et al. Inhibition of myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Research. 2010 Oct;30(10):4193-4200.
Fukazawa, Takuya ; Maeda, Yutaka ; Matsuoka, Junji ; Yamatsuji, Tomoki ; Shigemitsu, Kaoru ; Morita, Ichiro ; Faiola, Francesco ; Durbin, Mary L. ; Soucek, Laura ; Naomoto, Yoshio. / Inhibition of myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. In: Anticancer Research. 2010 ; Vol. 30, No. 10. pp. 4193-4200.
@article{223b82dc263b4f4e8b1e93dde3843834,
title = "Inhibition of myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc",
abstract = "Myc is an oncogenic transcription factor that promotes tumorigenesis. Recently, a dominant negative form of Myc (Omomyc) was shown to cause regression of lung tumors in a mouse model of lung cancer caused by KRAS mutation, suggesting that Myc might be a potential therapeutic target to treat the KRAS lung cancer. However, it is not yet known whether Omomyc can also inhibit the growth of human lung tumors that carry a similar KRAS mutation. In the present study, we demonstrate that Omomyc induces cell death of KRAS-mutated human lung adenocarcinoma A549 cells in vitro and in vivo. However, Omomyc does not induce cell death in human lung adenocarcinoma H441 cells that also carry the KRAS mutation. Interestingly, A549 cells express high levels of Myc, while H441 cells do not. Co-expression of exogenous Myc with Omomyc in H441 cells induces cell death, indicating that Omomyc requires high levels of Myc to induce cell death in KRAS mutation-positive lung adenocarcinoma. Here, we show for the first time that KRAS mutation-positive lung cancer displaying high levels of Myc could be treated by inhibiting Myc transactivation function.",
keywords = "A549, KRAS lung cancer, Myc, Omomyc",
author = "Takuya Fukazawa and Yutaka Maeda and Junji Matsuoka and Tomoki Yamatsuji and Kaoru Shigemitsu and Ichiro Morita and Francesco Faiola and Durbin, {Mary L.} and Laura Soucek and Yoshio Naomoto",
year = "2010",
month = "10",
language = "English",
volume = "30",
pages = "4193--4200",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Inhibition of myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc

AU - Fukazawa, Takuya

AU - Maeda, Yutaka

AU - Matsuoka, Junji

AU - Yamatsuji, Tomoki

AU - Shigemitsu, Kaoru

AU - Morita, Ichiro

AU - Faiola, Francesco

AU - Durbin, Mary L.

AU - Soucek, Laura

AU - Naomoto, Yoshio

PY - 2010/10

Y1 - 2010/10

N2 - Myc is an oncogenic transcription factor that promotes tumorigenesis. Recently, a dominant negative form of Myc (Omomyc) was shown to cause regression of lung tumors in a mouse model of lung cancer caused by KRAS mutation, suggesting that Myc might be a potential therapeutic target to treat the KRAS lung cancer. However, it is not yet known whether Omomyc can also inhibit the growth of human lung tumors that carry a similar KRAS mutation. In the present study, we demonstrate that Omomyc induces cell death of KRAS-mutated human lung adenocarcinoma A549 cells in vitro and in vivo. However, Omomyc does not induce cell death in human lung adenocarcinoma H441 cells that also carry the KRAS mutation. Interestingly, A549 cells express high levels of Myc, while H441 cells do not. Co-expression of exogenous Myc with Omomyc in H441 cells induces cell death, indicating that Omomyc requires high levels of Myc to induce cell death in KRAS mutation-positive lung adenocarcinoma. Here, we show for the first time that KRAS mutation-positive lung cancer displaying high levels of Myc could be treated by inhibiting Myc transactivation function.

AB - Myc is an oncogenic transcription factor that promotes tumorigenesis. Recently, a dominant negative form of Myc (Omomyc) was shown to cause regression of lung tumors in a mouse model of lung cancer caused by KRAS mutation, suggesting that Myc might be a potential therapeutic target to treat the KRAS lung cancer. However, it is not yet known whether Omomyc can also inhibit the growth of human lung tumors that carry a similar KRAS mutation. In the present study, we demonstrate that Omomyc induces cell death of KRAS-mutated human lung adenocarcinoma A549 cells in vitro and in vivo. However, Omomyc does not induce cell death in human lung adenocarcinoma H441 cells that also carry the KRAS mutation. Interestingly, A549 cells express high levels of Myc, while H441 cells do not. Co-expression of exogenous Myc with Omomyc in H441 cells induces cell death, indicating that Omomyc requires high levels of Myc to induce cell death in KRAS mutation-positive lung adenocarcinoma. Here, we show for the first time that KRAS mutation-positive lung cancer displaying high levels of Myc could be treated by inhibiting Myc transactivation function.

KW - A549

KW - KRAS lung cancer

KW - Myc

KW - Omomyc

UR - http://www.scopus.com/inward/record.url?scp=78650246896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650246896&partnerID=8YFLogxK

M3 - Article

C2 - 21036740

AN - SCOPUS:78650246896

VL - 30

SP - 4193

EP - 4200

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -